These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30136247)

  • 21. Neuroprotective effects of voluntary running on cognitive dysfunction in an α-synuclein rat model of Parkinson's disease.
    Crowley EK; Nolan YM; Sullivan AM
    Neurobiol Aging; 2018 May; 65():60-68. PubMed ID: 29407467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurobiological findings underlying depressive behavior in Parkinson's disease: A review.
    Mendonça IP; Duarte-Silva E; Chaves-Filho AJM; Andrade da Costa BLDS; Peixoto CA
    Int Immunopharmacol; 2020 Jun; 83():106434. PubMed ID: 32224442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurodegenerative signaling factors and mechanisms in Parkinson's pathology.
    Goswami P; Joshi N; Singh S
    Toxicol In Vitro; 2017 Sep; 43():104-112. PubMed ID: 28627426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms.
    Surdhar I; Gee M; Bouchard T; Coupland N; Malykhin N; Camicioli R
    Parkinsonism Relat Disord; 2012 Aug; 18(7):809-13. PubMed ID: 22652466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.
    Farzanehfar P
    Neurochem Res; 2016 Dec; 41(12):3161-3170. PubMed ID: 27613619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis].
    Storch A; Ebersbach G; Fuchs G; Jost WH; Odin P; Reifschneider G; Bauer M
    Fortschr Neurol Psychiatr; 2008 Dec; 76(12):715-24. PubMed ID: 19012223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Postnatal but Not Late Adult Neurogenesis Is Impaired in the Pitx3-Mutant Animal Model of Parkinson's Disease.
    Brandt MD; Krüger-Gerlach D; Hermann A; Meyer AK; Kim KS; Storch A
    Front Neurosci; 2017; 11():471. PubMed ID: 28883785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insight into the therapeutic role of the serotonergic system in Parkinson's disease.
    Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M
    Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson's disease patients.
    Riekkinen P; Kejonen K; Laakso MP; Soininen H; Partanen K; Riekkinen M
    Neuroreport; 1998 May; 9(7):1507-11. PubMed ID: 9631457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
    Santos-García D; de la Fuente-Fernández R
    J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease.
    Schwerk A; Altschüler J; Roch M; Gossen M; Winter C; Berg J; Kurtz A; Akyüz L; Steiner B
    Regen Med; 2015 May; 10(4):431-46. PubMed ID: 26022763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
    Pålhagen SE; Carlsson M; Curman E; Wålinder J; Granérus AK
    Acta Neurol Scand; 2008 May; 117(5):295-304. PubMed ID: 18279483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
    Prediger RD; Matheus FC; Schwarzbold ML; Lima MM; Vital MA
    Neuropharmacology; 2012 Jan; 62(1):115-24. PubMed ID: 21903105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of adult hippocampal neurogenesis: relevance to depression.
    Vaidya VA; Fernandes K; Jha S
    Expert Rev Neurother; 2007 Jul; 7(7):853-64. PubMed ID: 17610392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact and management of nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychotic symptoms in Parkinson's disease: pathophysiology and management.
    Bosboom JL; Wolters ECh
    Expert Opin Drug Saf; 2004 May; 3(3):209-20. PubMed ID: 15155149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bee venom for the treatment of Parkinson's disease: How far is it possible?
    Awad K; Abushouk AI; AbdelKarim AH; Mohammed M; Negida A; Shalash AS
    Biomed Pharmacother; 2017 Jul; 91():295-302. PubMed ID: 28477460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depressive symptoms in Parkinson's disease are related to decreased left hippocampal volume: correlation with the 15-item shortened version of the Geriatric Depression Scale.
    Goto M; Kamagata K; Hatano T; Hattori N; Abe O; Aoki S; Hori M; Gomi T
    Acta Radiol; 2018 Mar; 59(3):341-345. PubMed ID: 28691530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity.
    Regensburger M; Prots I; Winner B
    Neural Plast; 2014; 2014():454696. PubMed ID: 25110593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.